论文部分内容阅读
目的比较司帕沙星(SPLX)与洛美沙星(LMLX)的临床抗感染作用。方法将24例呼吸道和泌尿道等感染患者随机分为SPLX和LMLX两组。SPLX组口服剂量为200～300mg ,每日1次 ;LMLX组口服剂量为200～400mg,每日2次。临床疗效按痊愈、显效、进步和无效四级标准判定。痊愈和显效合计为有效。结果SPLX组的总用药量显著少于LMLX组 ,但痊愈率和有效率略高于LMLX组。受试患者的细菌分离率为91 7 % ,在停药第11天两组的细菌清除率为81 8 %和75 0 %。两组均未观察到药物不良反应。结论SPLX为治疗细菌性感染的安全有效的氟喹诺酮类药物 ,其效应/剂量比要高于洛美沙星
Objective To compare the clinical anti-infective effects of sparfloxacin (SPLX) and lomefloxacin (LMLX). Methods Twenty-four patients with respiratory and urinary tract infections were randomly divided into two groups: SPLX and LMLX. The oral dose of SPLX group was 200-300 mg once daily and the oral dose of LMLX group was 200-400 mg twice daily. Clinical efficacy according to cure, markedly effective, progressive and ineffective four criteria. Healed and markedly effective as a total. Results The total dosage of SPLX group was significantly less than that of LMLX group, but the cure rate and efficiency were slightly higher than that of LMLX group. The bacterial isolation rate of the tested patients was 91.7%. The bacterial clearance rates of the two groups on the 11th day of treatment were 81 8% and 75 0%. No adverse drug reactions were observed in either group. Conclusion SPLX is a safe and effective fluoroquinolone for the treatment of bacterial infections, and its effect / dose ratio is higher than that of lomefloxacin